For Health Care Professionals Outside the US

In adult patients with chronic hepatitis C virus–associated thrombocytopenia (HCVaT)

REVOLADE Enabled Patients
To Initiate Antiviral Therapy

In the initiation phase (which lasted between 2 and 9 weeks), nearly all patients with low platelet counts were able to initiate peginterferon-based antiviral therapy after treatment with REVOLADE1,2

Review the ENABLE-1 and ENABLE-2 study designs
  • The majority of patients taking REVOLADE maintained a platelet count >50 x 109/L in the antiviral treatment phase of the studies (24 weeks or 48 weeks, depending on HCV genotype)1
    • ENABLE-1: 69% with REVOLADE vs 15% with placebo
    • ENABLE-2: 81% with REVOLADE vs 23% with placebo
REVOLADE helps patients on antiviral therapy to achieve sustained virologic response.1.2 (see the data below)

In adult patients with chronic HCVaT

REVOLADE Enabled More Patients to Achieve
Sustained Virologic Response

Significantly more patients taking REVOLADE, in addition to peginterferon-based antiviral therapy, achieved sustained virologic response in the ENABLE studies2
Review the ENABLE-1 and ENABLE-2 study designs

References:

1. Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442-452. 2. REVOLADE Summary of Product Characteristics. February 2019.

© 2019 Novartis | Use of this website is subject to our Terms of Use
Disclaimer: This is an international website for REVOLADE® (eltrombopag) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents links at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.